Recent Publications

Refereed Publications

Journals

• Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017 Oct;96(10):1653-1665.
• Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O’Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335.
• Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016 Dec;101(12):e482-e484
• Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016 Oct;57(10):2464-7.
• Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73.
• Williamson BT, Foltz L, Leitch HA. Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome. Hematol Rep. 2016 May 10;8(2):6480.
• Bestawros A, Foltz L, Srour N, Savage KJ, Connors JM. Patients’ and physicians’ roles in detecting recurrent Hodgkin lymphoma following complete remission. Ann Oncol. 2012 Dec 9.
• Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res. 2012 Nov;36(11):1380-6.
• Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA. Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era. Adv Hematol. 2012;2012:910954.
• Peterson EA, Zypchen L, Lee VH, Foltz LM. Published guidelines versus real-life practice in the diagnosis and treatment of essential thrombocythemia. Am J Hematol 2011: 86(9):792-4.
• Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40-8.
• Foltz L, Song K, Connors J. Hodgkin’s lymphoma in adolescents. J Clin Oncol 2006; 24(16): 2520-2526.
• Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsburger C. Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 81: 210-211, 2006.
• Duncan (Foltz) L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease with serum creatinine: who are we missing? Nephrol Dial Transplant 2001; 16: 1042-1046.
• Levin A, Duncan (Foltz) L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, Dumas R, Ross S. A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 2000; 53: 140-146.
• Sirrs S, Duncan (Foltz) L, Djurdjev O, Nussbaumer G, Ganz G, Frohlich J and Levin A. Homocysteine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant 1999; 14: 738-743.

Non-Refereed Publications

Journals

• Busque L, Porwit A, Day R, Olney HJ, Leber B, Ethier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group. Am J Clin Pathol. 2016 Oct;146(4):408-22.
• Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clin Lymphoma Myeloma Leuk. 2015 Dec; 15912):715-27.
• Gupta V, Foltz L, Sirhan S, Busque L, Turner AR. Emerging therapeutic options for myelofibrosis; a Canadian perspective. Am J Blood Res. 2012;2(3):170-86.
• Lin Y and Foltz L. Proposed guidelines for platelet transfusion. BC Med J 2005;47(5):245-248.

Abstracts

• Lynda Foltz, Gian-Matteo Pica, Hacene Zerazhi, Jan Van Droogenbroeck, Sorin Visanica, Enrique Báez de la Fuente, Brian Leber, Antonio Medina de Almeida, Dana Ranta, Mauricio Reyes Cartes, Jean-Jacques Kiladjian, Linda Chrit, Zhaoyu Yin, Juliane Morando and Timothy Devos. Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available. American Society of Hematology, Poster Presentation, 2018.
• Srdan Verstovsek, Ruben Mesa, Olga Pozdnyakova, Robert Hasserjian, John Mascarenhas, Lynda Foltz, Ellen Ritchie, Richard Silver, Marina Kremyanskaya, Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Zeev Estrov, Bernt Vandenblink, Renu Gupta, Jason Gotlib. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. American Society of Hematology Oral Presentation, 2018.
• Wasithep Limvorapitak, Jeremy Parker, Lynda Foltz, Aly Karsan. Outcomes of Patients with Low Variant Allele Fraction JAK2V617F: a 5-year Retrospective Analysis. American Society of Hematology Poster Presentation, 2018.
• Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Pia Raanani. Predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3B expanded-access JUMP study. European Hematology Association Meeting Poster 2018.
• Paola Guglielmelli, Pia Raanani, Renato Tavares, Lynda Foltz, Bruno Martino, Elza Lomaia, Martin Griesshammer, Haifa Kathrin Al-Ali, Vikas Gupta, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Pilar Giraldo. Safety and efficacy of ruxolitinib in patients with DIPSS low-risk myelofibrosis in the phase 3B expanded-access JUMP study. European Hematology Association Meeting Poster 2018.
• Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Parvis Sadjadian, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Alessandro M. Vannucchi. JUMP: A Phase 3B expanded-access study comparing the safety and efficacy of Ruxolitinib (Rux) in patients with Dynamic International Prognostic Scoring System (DIPSS) low/intermediare-1-, intermediate-2- and high risk myelofibrosis. European School of Hematology International Conference on MPN 2018, Oral presentation.
• Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritske*, Renato Tavares, Martin Griesshammer, Vikas Gupta, Pia Raanani, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli and Alessandro M. Vannucchi. Primary Analysis of Jump, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233). Blood 2017 130:4204; American Society of Hematology, Poster 2017.
• Timothy Devos, Gian-Matteo Pica, Hacene Zerazhi, Jan Van Droogenbroeck, Sorin Visanica, Enrique Baez de la Fuente, Brian Leber, Antonio Medina de Almeida, Dana Ranta,Tomasa Martinez, Jean-Jacques Kiladjian, Linda Chrit, Zhaoyu Yin, Julian Perez Ronco, Lynda Foltz. Safety and Efficacy of Ruxolitinib (rux) in an Open-label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No AlternativeTreatments Are Available. Blood 2017 130:2918 American Society of Hematology, Poster 2017.
• Lynda Foltz, Steffen Koschmieder, Claire N. Harrison, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa. Perception of symptom burden and treatment goals between physicians and patients with MPNs: An analysis from the international MPN Landmark Survey. European Hematology Association Meeting e-poster 2017.
• Lynda Foltz, Bruno Martino, Andrey Zaritskey, Renato Tavares, Pilar Giraldo, Haifa Kathrin Al-Ali, Paola Guglielmelli, Vikas Gupta, Pia Raanani9 Catherine Bouard,1 Julian Perez Ronco,1 Ranjan Tiwari,1 Martin Griesshammer. Safety and efficacy of ruxolitinib in patients with myelofibrosis who started treatment at 10 mg BID and were uptitrated in the phase 3B expanded-access JUMP study. European Hematology Association Meeting e-poster, 2017.
• Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Griesshammer, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Alessandro M. Vannucchi. Comparing the safety and efficacy of ruxolitinib in patients with DIPSS low/intermediate-1, intermediate-2 and high risk myelofibrosis in JUMP, a phase 3B expanded access study. European Hematology Association Meeting e-poster 2017.
• Steffen Koschmieder, Michael Koehler, Paola Guglielmelli Ruben A. Mesa, Lynda Foltz, Tina Flindt, Jonathan Mathias7 Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, and Claire N. Harrison. Treatment and management of patients with MPNs- findings from the international MPN Landmark survey. European Hematology Association Meeting Poster 2017
• Pia Raanani, Vikas Gupta, Parvis Sadjadian, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Lynda Foltz, Renato Tavares, Andrey Zaritskey, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Bruno Martino. Safety and Efficacy of ruxolitinib in elderly patients (>75 years) with myelofibrosis: An analysis from the phase 3B expanded access JUMP study. European Hematology Association Meeting Poster 2017.
• Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, Haifa Kathrin Al-Ali, Anna Marina Liberati, Philipp D. Le Coutre, Alessandro M. Vannucchi, Carmen Garcia-Hernandez, Renato Tavares, Martin Griesshammer, Vikas Gupta, Pia Raanani, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, Sadhvi Khanna, Andrey Zaritskey. Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233) Blood 2016 128:3107; American Society of Hematology Meeting Poster 2016.
• Claire Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa. The Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Quality of Life and Productivity: Results from the International MPN Landmark Survey. Blood 2016 128:4267; American Society of Hematology Poster 2016.
• Haifa Kathrin Al-Ali, Renato Tavares, Giuseppe A. Palumbo, Francesca Palandri, Bruno Martino, Anna Marina Liberati,Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo,Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi and Philipp Le Coutre. Safety and Efficacy of Ruxolitinib in Expanded-Access JUMP Study: An Update From a Cohort of 1869 Patients. Deutsche Gesellschaft für Hämatologie und Onkologie Oral presentation 2016.
• Francesco Passamonti, Andrey Zaritskey, Pilar Giraldo, Anna Marina Liberati, Dietger Niederwieser, Francesca Palandri, Pia Raanani,Martin Griesshammer,Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, Vikas Gupta, Bruno Martino, Lynda Foltz, Julian Perez Ronco, Jagannath Ghosh, Catherine Bouard, Renato Tavares. Safety and Efficacy of Ruxolitinib in Patients with DIPSS Intermediate-1 Rish Myelofibrosis from JUMP: An Open-Label, Multicenter, Single-arm Expanded Access Study. European Hematology Association Meeting Poster 2016.
• Pilar Giraldo, Francesca Palandri, Giuseppe A. Palumbo, Andrey Zaritskey, Aleksander Skotnicki, Timothy Devos, Domingo Saavedra, Martin Griesshammer, Haifa Kathrin Al-Ali Renato Tavares, Alessandro M. Vannucchi, Vikas Gupta, Pia Raanani, Bayane Tannir, Jagannath Ghosh, Julian Perez Ronco, Lynda Foltz. Safety and Efficacy of Ruxolitinib in Patient with Intermediate-1 Risk Myelofibrosis from an Open-Label, Multicenter, Single-arm Expanded Access Study. European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.
• Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez-Ronco, Lynda Foltz. Effects of Ruxolitinib Treatment on the Prognostic Impact of Anemia in Patients with Myelofibrosis. European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.
• Renato Tavares, Giuseppe A. Palumbo, Philipp Le Coutre, Francesca Palandri, Haifa Kathrin Al-Ali, Bruno Martino, Anna Marina Liberati, Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh,Bayane Tannir, Julian Perez Ronco, and Alessandro M. Vannucchi MD.
  Safety and Efficacy of Ruxolitinib in Expanded-Access JUMP Study: An Update From a Cohort of 1869 Patients; European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Meeting Poster, 2016.
• Srdan Verstovsek, Ruben A. Mesa, Lynda M Foltz, Vikas Gupta, John O. Mascarenhas, Ellen K. Ritchie, Ronald Hoffman, Richard Silver, Marina Kremyanskaya, Olga Pozdnyakova, Robert P. Hasserjian, Elizabeth Trehu, Mohamed E Salama, Hagop M Kantarjian, Jason Gotlib. PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks.
  Blood 2015 126:56; American Society of Hematology Meeting Oral Presentation 2015.
• Vikas Gupta, Claire N. Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, Wei Peng, Prashanth Gopalakrishna, Hagop Kantarjian, Srdan Verstovsek. The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies. Blood 2015 126:1604.
  American Society of Hematology Meeting Oral Presentation 2015.
• Renato Tavares, Giuseppe A. Palumbo, Philipp Le Coutre, Francesca Palandri, Haifa KathrinAl-Ali, Bruno Martino, Anna Marina Liberati, Jose Grasa Ullrich, Massimo Breccia, David Brittain, Lynda Foltz, Martin Griesshammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi. Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. Blood 2015 126:2799; American Society of Hematology Meeting Poster Presentation 2015.
• Verstovsek S, Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta B, Mascarenhas J, Ritchie E, Hoffman R, Silver R, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J. Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151. Society Hematologic Oncology, Poster Presentation 2015.
• Olga Pozdnyakova,Robert Hasserjian, Mohamed Salama, Ruben Mesa, Lynda Foltz, Vikas Gupta, John Mascarenhas, Ellen Ritchie, Ronald Hoffman, Richard Silver, Marina Kremyanskaya, Elizabeth Trehu, Hagop Kantarjian, Jason Gotlib, Srdan Verstovsek. Bone marrow reticulin fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and is associated with normalization of megakaryocyte morphology and improved platelet counts. European Hematology Association Meeting Poster Presentation 2015.
• Pilar Giraldo, Francesca Palandri, Giuseppe A. Palumbo, Andrey Zaritskey, Aleksander Skotnicki, Timothy Devos, Domingo Saavedra, Martin Griesshammer, Haifa Kathrin Al-Ali Renato Tavares, Alessandro M. Vannucchi, Vikas Gupta, Pia Raanani, Bayane Tannir, Jagannath Ghosh, Julian Perez Ronco, Lynda Foltz. Safety and Efficacy of Ruxolitinib in Patient with Intermediate-1 Risk Myelofibrosis from an Open-Label, Multicenter, Single-arm Expanded Access Study. European Hematology Association Meeting Poster Presentation 2015.
• Al-Ali H, Le Coutre P, Schlag R, Griesshammer M, Tavares R, Martin B, Vannucchi A, Castellano P, Foltz L, Raanani P, Tannir B, Ghosh J, Perez Ronco J, Gupta V. The Safety and Efficacy of Ruxolitinib in an Open-Label Phase 3B Expanded-Access Study in Myelofibrosis Patients. European School of Hematology Meeting Poster, 2014.
• Haifa Kathrin Al-Ali, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Julian Perez Ronco and Lynda M Foltz, Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF) Blood 2014 124:4583; American Society of Hematology Meeting Poster Presentation 2014.
• Srdan Verstovsek, Ruben A. Mesa, Lynda M Foltz, Vikas Gupta, John O Mascarenhas, Ellen K. Ritchie, Ronald Hoffman, Richard T. Silver, Marina Kremyanskaya, Olga Pozdnyakova, Robert P Hasserjian, MD11, Elizabeth Trehu, Hagop M. Kantarjian and Jason R. Gotlib. Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Blood 2014 124:713; American Society of Hematology Meeting Oral Presentation 2014.
• Griesshammer M, Vannucchi A, le Coutre P, Tavares R, Al-Ali H, Raanani P, Gupta V, Foltz L, Giraldo P, Bouard C, Perez Ronco J, Ghosh J, Martino B. Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF). Blood 2014 124:1859; American Society of Hematology Meeting Poster Presentation 2014.
• Mascarenhas J,Talpaz M, Gupta V, Foltz L, Savona M, Paquette R, Turner R, Paul Coughlin, Elliott Winton, MD, Deborah Hunter, Albert Assad, Jason Clark, Peter O’Neill, Ronald Hoffman, Srdan Verstovsek. Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis. Blood 2014 124:714; American Society of Hematology Meeting Oral Presentation 2014.
• Bruno Martino, Philipp le Coutre, Martin Griesshammer, Thomas Illmer, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, Renato S Tavares, Alessandro M. Vannucchi, MD, Pilar Giraldo, Lynda M Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jaggannath Ghosh and Haifa Kathrin Al-Ali. Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update. Blood 2014 124:3197; American Society of Hematology Meeting Poster Presentation 2014.
• Bestawros A, Foltz L, Srour N, Connors J. Patients’ versus physicians’ roles in detecting recurrent Hodgkin lymphoma. J Clin Oncol 2011: 29: 8041.
  Poster Presentation American Society of Clinical Oncology, 2011.
• Leitch H, Chan C, Leger C, Foltz L, Ramadan K, Vickars L. Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Associated in Patients with a Non-RARS Diagnosis. Blood 2011; 118: 1732.
  Poster Presentation, American Society of Hematology Annual Meeting, 2011.
• Ambler K, Vickars L, Leger C, Foltz L, Montaner J, Harris M, Leitch H. Clinical Features, Treatment and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura in the HAART Era. Blood, 2010, 116: 2522.
  Poster Presentation, American Society of Hematology Annual Meeting, 2010.
• Lee V, Peterson E, Zypchen L, Foltz LM. Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice. Blood 2009: 114: 1903.
  Poster Presentation, American Society of Hematology Annual Meeting, 2009.
• Peterson E, Zypchen L, Nitta J, Berkowitz J, Foltz LM. Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia. Blood 2009: 114:2916.
  Poster Presentation, American Society of Hematology Annual Meeting, 2009.
• MacKenzie-Feder J, Eaves C, Lambie K, Abdi-Ali A, Ramadan K, Young S, Horsman D, Galbraith P, Eaves A, Foltz L. Role of serum erythropoietin, erythropoietin-independent erythroid colony formation and bone marrow assessment in the diagnosis of polycythemia vera in patients with JAK2 V617F mutation. J Clin Oncol 2009, 27: 7085.
  Poster Presentation American Society of Clinical Oncology, 2009.
• Leitch H, Ezzat H, Rollins M, Goodman T, Leger C, Wong D, Ramadan K, Foltz L, Vickars L. Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis Receiving Iron Chelation Therapy. Blood 2008: 112:1748.
  Poster Presentation, American Society of Hematology Annual Meeting, 2008
• Alipour S, Leitch H, Vickars L, Foltz LM, Galbraith P, Leger C, Ramadan K. Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome. Blood 2008: 112:3179.
  Poster Presentation, American Society of Hematology Annual Meeting, 2008
• Foltz L, Song K, Connors, J. Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician? Blood 2004; 104 (11): 3124.
  Poster Presentation, American Society of Hematology Annual Meeting, 2004
• Foltz L, Galbraith P. Autoimmune Hemolytic Anemia and HIV.
  Poster presentation, ACP-ASIM Annual Meeting, 2002 ,
  Duncan (Foltz) L, Heathcote J, Djurdjev O, Levin A. Screening for Renal Disease with Serum Creatinine: Who are we missing? JASN, 1998; 9: 153A
  Poster presentation, American Society of Nephrology Annual Meeting, 1998
• Duncan (Foltz) L, Luscombe R, Whitlam L, Nussbaumer G, Werb R, Levin A. Infection and malfunction in temporary and permanent hemodialysis catheters: assessment of similarities and differences.
  Poster presentation, Canadian Society of Nephrology Annual Meeting, 1998
• Levin A, Duncan (Foltz) L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, Ross S. A randomized placebo-controlled double-blind trial of lipid lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Invest Med, 1997; 20(4) supplement; S68.
  Oral Presentation, American Society of Nephrology Annual Meeting, 1997.